CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 179 enrolled
Drug / intervention
Alogliptin and voglibose +1 moredrug
Likely dose
Alogliptin and voglibose 12.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01263509
NCT01263509Phase 3Completed
CompareCT.gov

A Long-term, Open-label Extension Study to Investigate the Long-term Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan

Takeda·interventional·Posted Dec 20, 2010·Updated Feb 3, 2012

In Brief

A Phase 3 clinical trial evaluating Alogliptin and voglibose for Type 2 Diabetes Mellitus. Completed, enrolled 179 participants.

Detailed Summary

The purpose of this study was to evaluate the long-term safety and efficacy of alogliptin and an α-glucosidase inhibitor administered once daily (QD) or three times daily (TID) for 40 consecutive weeks in participants who completed a phase 2/3 α-glucosidase inhibitor add on study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 20, 2010
Enrollment StartJun 1, 2007
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.5 years ago

Interventions

Alogliptin and voglibosedrug

Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.

Alogliptin and voglibosedrug

Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.